DXCM News and Press, DexCom Inc. From 07/15/22

The Strategy underperformed during another difficult quarter for growth stocks, with weakness centered among several COVID-19 beneficiaries that are seeing tough comparisons, rising input costs or both. Positioning moves during the quarter remained focused on promoting stability and i...

DexCom ( NASDAQ: DXCM ) stock rose as much as 4% to $79.55 in Friday trading amidst stronger broader U.S. markets , with shares also helped by Bernstein research initiating the company with an outperform rating. Bernstein analyst Lee Hambright in a research note date...

If you've had sticker shock while perusing the grocery store recently and decided not to buy something you normally would, DexCom (NASDAQ: DXCM) might not be the stock for you. The medical device company's status as a solid growth stock is much the same as it ever was, but it's not ...

This month, video game retailer GameStop (NYSE: GME) announced that it will deploy a 4-for-1 stock split. The following day, the popular meme stock jumped more than 15%. While news of the split (to occur July 21) may be exciting for retail investors, this action on its own isn't a r...

We may have seen the bottom already. The S&P 500 is up 6.4% in 2 weeks. The NASDAQ is up 9.2%. The market is trying to tell us something. A long climb down the mountain Here is a year-to-date chart of the S&P 500 index. Was the June 16 th low of 3...

DexCom has a leading position in a huge and growing market of continuous glucose monitoring. Medical technology is a growing space, with powerful demographic forces leading to outsized long-term growth. The stock has pulled back to an entry point that has it a strong buy for a 5+ ...

While growth rates are constantly slowing down for DexCom, the company is still reporting impressive top line numbers. Considering the increasing competition, the potential recession and maybe smaller market than estimated should make us question the optimistic growth assumptions for ...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...

Philippe Laffont’s 13F portfolio value decreased from $22.55B to $13.67B this quarter. They increased Block Inc., DoorDash, Netflix, Uber, and Peloton Interactive while dropping Applied Materials, Pfizer, Lam Research, Kanzhun Limited, and Confluent. Their top three positio...

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022. Management will hold a conference call to review the company's second quarter 2022 performance starting at 4:30 p.m. (Eastern ...